Development of a Deep Learning Model to Identify Lymph Node Metastasis on Magnetic Resonance Imaging in Patients with Cervical Cancer
Qingxia Wu, PhD, Shuo Wang, PhD, Shuixing Zhang, MD, PhD, Meiyun Wang, MD, Yingying Ding, MD, PhD, Jin Fang, MD, Qingxia Wu, MD, Wei Qian, PhD, Zhenyu Liu, PhD, Kai Sun, PhD, Yan Jin, MD, He Ma, PhD, and Jie Tian, PhD.
Accurate identification of lymph node metastasis preoperatively and noninvasively in patients with cervical cancer can avoid unnecessary surgical intervention and benefit treatment planning.
To develop a deep learning model using preoperative magnetic resonance imaging for prediction of lymph node metastasis in cervical cancer.
This diagnostic study developed an end-to-end deep learning model to identify lymph node metastasis in cervical cancer using magnetic resonance imaging (MRI). A total of 894 patients with stage IB to IIB cervical cancer who underwent radical hysterectomy and pelvic lymphadenectomy were reviewed. All patients underwent radical hysterectomy and pelvic lymphadenectomy, received pelvic MRI within 2 weeks before the operations, had no concurrent cancers, and received no preoperative treatment. To achieve the optimal model, the diagnostic value of 3 MRI sequences was compared, and the outcomes in the intratumoral and peritumoral regions were explored. To mine tumor information from both image and clinicopathologic levels, a hybrid model was built, and its prognostic value was assessed by Kaplan-Meier analysis. The deep learning model and hybrid model were developed on a primary cohort consisting of 338 patients (218 patients from Sun Yat-sen University Cancer Center, Guangzhou, China, between January 2011 and December 2017 and 120 patients from Henan Provincial People’s Hospital, Zhengzhou, China, between December 2016 and June 2018). The models then were evaluated on an independent validation cohort consisting of 141 patients from Yunnan Cancer Hospital, Kunming, China, between January 2011 and December 2017.
The primary diagnostic outcome was lymph node metastasis status, with the pathologic characteristics diagnosed by lymphadenectomy. The secondary primary clinical outcome was survival. The primary diagnostic outcome was assessed by receiver operating characteristic (area under the curve [AUC]) analysis; the primary clinical outcome was assessed by Kaplan-Meier survival analysis.
A total of 479 patients (mean [SD] age, 49.1 [9.7] years) fulfilled the eligibility criteria and were enrolled in the primary (n = 338) and validation (n = 141) cohorts. A total of 71 patients (21.0%) in the primary cohort and 32 patients (22.7%) in the validation cohort had lymph node metastasis confirmed by lymphadenectomy. Among the 3 image sequences, the deep learning model that used both intratumoral and peritumoral regions on contrast-enhanced T1-weighted imaging showed the best performance (AUC, 0.844; 95% CI, 0.780-0.907). These results were further improved in a hybrid model that combined tumor image information mined by deep learning model and MRI-reported lymph node status (AUC, 0.933; 95% CI, 0.887-0.979). Moreover, the hybrid model was significantly associated with disease-free survival from cervical cancer (hazard ratio, 4.59; 95% CI, 2.04-10.31; P < .001).
The findings of this study suggest that deep learning can be used as a preoperative noninvasive tool to diagnose lymph node metastasis in cervical cancer.
The American Cancer Society estimates an incidence of 13,800 new cases of invasive cervical cancer and a death rate of 4,290 in 2020, although the death rate has decreased since the use of the Pap test. Accurate identification of lymph node (LN) status preoperatively in patients with cervical cancer helps avoid unnecessary surgical intervention and assists treatment planning. Traditional imaging methods used for this purpose (MRI for LN size assessment) have limited sensitivity and significantly impact treatment decisions. This study proposes a Deep Learning (DL) model with two outcomes: 1) Identification of Lymph Node Metastasis (LNM) using MRI CET1WI of the tumor and peritumoral area and 2) Determination of the disease-free survival (DSF) rate. This method showed a sensitivity of >90% and a specificity of >87%. Rather than using previous methods such as radiomic analysis, which requires invasive assessments, expert availability, and data analysis, the DL model is an adequate, non-invasive assessment that is less time-consuming to get the proper disease management. This method has shown promising performance in patients with thoracic, breast, and Alzheimer’s disease.